Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review

Marina Ulanova; Anne Poljak; Wei Wen; Andre Bongers; Lucy Gloag; Justin Gooding; Richard Tilley; Perminder Sachdev; Nady Braidy

doi:10.2217/nnm-2019-0316

Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review

Marina Ulanova, Anne Poljak, Wei Wen, Andre Bongers, Lucy Gloag, Justin Gooding, Richard Tilley, Perminder Sachdev, Nady Braidy^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

29 Citations (Scopus)

Abstract

Nanoparticle (NP)-based magnetic contrast agents have opened the potential for MRI to be used for early diagnosis of Alzheimer’s disease (AD). This article aims to review the current progress of research in this field. A comprehensive literature search was performed based on PubMed, Medline, EMBASE, PsychINFO and Scopus databases using the following terms: ‘Alzheimer’s disease’ AND ‘nanoparticles’ AND ‘Magnetic Resonance Imaging.’ 33 studies were included that described the development and utility of various NPs for AD imaging, including their coating, functionalization, MRI relaxivity, toxicity and bioavailability. NPs show immense promise for neuroimaging, due to superior relaxivity and biocompatibility compared with currently available imaging agents. Consistent reporting is imperative for further progress in this field.

Original language	English
Pages (from-to)	725-743
Number of pages	19
Journal	Nanomedicine
Volume	15
Issue number	7
DOIs	https://doi.org/10.2217/nnm-2019-0316
Publication status	Published - Mar 2020
Externally published	Yes

Access to Document

10.2217/nnm-2019-0316

Cite this

@article{3966a909a04742d99fcd0c6cad61a3cf,

title = "Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer{\textquoteright}s Disease: A Systematic Review",

abstract = "Nanoparticle (NP)-based magnetic contrast agents have opened the potential for MRI to be used for early diagnosis of Alzheimer{\textquoteright}s disease (AD). This article aims to review the current progress of research in this field. A comprehensive literature search was performed based on PubMed, Medline, EMBASE, PsychINFO and Scopus databases using the following terms: {\textquoteleft}Alzheimer{\textquoteright}s disease{\textquoteright} AND {\textquoteleft}nanoparticles{\textquoteright} AND {\textquoteleft}Magnetic Resonance Imaging.{\textquoteright} 33 studies were included that described the development and utility of various NPs for AD imaging, including their coating, functionalization, MRI relaxivity, toxicity and bioavailability. NPs show immense promise for neuroimaging, due to superior relaxivity and biocompatibility compared with currently available imaging agents. Consistent reporting is imperative for further progress in this field.",

keywords = "Alzheimer's disease, contrast agents, diagnosis, MRI, nanoparticles",

author = "Marina Ulanova and Anne Poljak and Wei Wen and Andre Bongers and Lucy Gloag and Justin Gooding and Richard Tilley and Perminder Sachdev and Nady Braidy",

note = "Publisher Copyright: {\textcopyright} 2020 Future Medicine Ltd.",

year = "2020",

month = mar,

doi = "10.2217/nnm-2019-0316",

language = "English",

volume = "15",

pages = "725--743",

journal = "Nanomedicine",

issn = "1743-5889",

publisher = "Future Medicine Ltd.",

number = "7",

}

TY - JOUR

T1 - Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review

AU - Ulanova, Marina

AU - Poljak, Anne

AU - Wen, Wei

AU - Bongers, Andre

AU - Gloag, Lucy

AU - Gooding, Justin

AU - Tilley, Richard

AU - Sachdev, Perminder

AU - Braidy, Nady

PY - 2020/3

Y1 - 2020/3

N2 - Nanoparticle (NP)-based magnetic contrast agents have opened the potential for MRI to be used for early diagnosis of Alzheimer’s disease (AD). This article aims to review the current progress of research in this field. A comprehensive literature search was performed based on PubMed, Medline, EMBASE, PsychINFO and Scopus databases using the following terms: ‘Alzheimer’s disease’ AND ‘nanoparticles’ AND ‘Magnetic Resonance Imaging.’ 33 studies were included that described the development and utility of various NPs for AD imaging, including their coating, functionalization, MRI relaxivity, toxicity and bioavailability. NPs show immense promise for neuroimaging, due to superior relaxivity and biocompatibility compared with currently available imaging agents. Consistent reporting is imperative for further progress in this field.

AB - Nanoparticle (NP)-based magnetic contrast agents have opened the potential for MRI to be used for early diagnosis of Alzheimer’s disease (AD). This article aims to review the current progress of research in this field. A comprehensive literature search was performed based on PubMed, Medline, EMBASE, PsychINFO and Scopus databases using the following terms: ‘Alzheimer’s disease’ AND ‘nanoparticles’ AND ‘Magnetic Resonance Imaging.’ 33 studies were included that described the development and utility of various NPs for AD imaging, including their coating, functionalization, MRI relaxivity, toxicity and bioavailability. NPs show immense promise for neuroimaging, due to superior relaxivity and biocompatibility compared with currently available imaging agents. Consistent reporting is imperative for further progress in this field.

KW - Alzheimer's disease

KW - contrast agents

KW - diagnosis

KW - MRI

KW - nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=85082146856&partnerID=8YFLogxK

U2 - 10.2217/nnm-2019-0316

DO - 10.2217/nnm-2019-0316

M3 - Review article

C2 - 32141799

AN - SCOPUS:85082146856

SN - 1743-5889

VL - 15

SP - 725

EP - 743

JO - Nanomedicine

JF - Nanomedicine

IS - 7

ER -

Nanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review

Abstract

Access to Document

Other files and links

Fingerprint

Cite this